Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $2.5 million.

  • Seres Therapeutics' Share-based Compensation fell 5211.27% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 4883.37%. This contributed to the annual value of $21.0 million for FY2024, which is 3850.33% down from last year.
  • Seres Therapeutics' Share-based Compensation amounted to $2.5 million in Q3 2025, which was down 5211.27% from $2.3 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year Share-based Compensation high stood at $13.5 million for Q2 2023, and its period low was $2.3 million during Q2 2025.
  • In the last 5 years, Seres Therapeutics' Share-based Compensation had a median value of $5.5 million in 2024 and averaged $5.7 million.
  • In the last 5 years, Seres Therapeutics' Share-based Compensation surged by 16530.83% in 2021 and then crashed by 5898.31% in 2024.
  • Over the past 5 years, Seres Therapeutics' Share-based Compensation (Quarter) stood at $5.7 million in 2021, then grew by 28.5% to $7.3 million in 2022, then tumbled by 30.24% to $5.1 million in 2023, then fell by 25.97% to $3.8 million in 2024, then tumbled by 34.08% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.3 million for Q2 2025, and $2.8 million during Q1 2025.